Office of the Clinical Director

2022/2023年，美国国立卫生研究院(NIH)国家药物滥用研究所(NIDA)临床主任办公室(OCD)、内部研究计划(IRP)、国家药物滥用研究所(NIDA)为(6)独立实验室/临床调查人员(4名终身教职跟踪/单位负责人和2名高级调查人员/分支机构负责人)和一名最近卸任的核心/机构负责人提供临床研究支持。2022年1月，临床主任和副主任都卸任，任命了一名代理临床主任和代理副临床主任；这两个职位现在都是长期任用。目前正在进行包括人员和工作流程在内的业务变化，包括在不与外部供应商续签合同协议后，将参与者征聘工作转移到内部管理。NIDA IRP目前的临床研究组合包括各种合作研究，重点是： 成瘾新疗法的安全性和有效性。 影响吸毒和复发的因素。 应用基于磁共振成像的结构和功能成像来阐明急性和慢性药物效应及其对认知过程的影响。 易对成瘾物质产生依赖的个体差异的分子遗传学基础。 开发先进的功能和结构磁共振成像/光谱学技术。 结构磁共振技术，以评估与脑功能障碍相关的组织完整性。 经颅磁刺激在成瘾障碍诊断和治疗中的作用。 用于现场实时成瘾治疗干预的移动健康应用程序。 NIDA IRP临床组合的愿景是建立一个高度翻译的计划，进行尖端成瘾研究，旨在提高我们对成瘾相关机制的理解，并为物质使用障碍患者开发新的治疗方法，从新的行为方法到基于药物和神经调节的新治疗方法。为了实现这一愿景，除其他行动外，以下是正在进行的关键目标：(1)创建统一和协调的临床组合；(2)建立、培育和支持NIDA临床PIs和NIDA IRP中的临床前PIs之间的协作项目；(3)建立、培育和支持NIDA IRP的临床PIs与其他研究所/中心、学术和私营部门的其他临床和临床前PIs之间的协作项目；(4)使NIDA IRP的临床组合成为整个NIH IRP的核心组成部分，通过强大和长期的科学和临床合作，以及NIDA IRP和NIH其他IC/中心/办公室之间同样强大和长期的合作，提高其在整个NIH的中心作用和知名度(包括在NIH贝塞斯达的NIH主校区)；(5)成为如何促进和维持多样性、公平、包容和可获得性的文化的典范；(6)加强与当地大学的合作，促进华盛顿-马里兰州-弗吉尼亚州(DMV)地区的社区外展活动；以及(7)创建学院-NIH联合临床培训计划合作，并为未来一代临床医生和临床科学家提供与成瘾相关的教育/培训，以促进成瘾科学和医学的发展。 总而言之，NIDA IRP临床组合的愿景是建立、培育、加强和支持一个合作的实验室小组，通过不同的途径和方法跨越翻译研究，服务于我们推进成瘾科学和医学的共同目标。这一愿景包括创新的临床成瘾研究，通过与基础科学的双向转换项目进一步证实，并通过大规模人口研究进一步扩展。CD及其OCD团队的目标是提供科学的临床领导，并提供监督、指导、指导和支持，旨在加强以患者为导向的杰出科学家和临床医生团队，他们具有不同和协同的背景，范围从医学和实验心理学到神经成像、神经科学和健康沟通。

In 2022/2023, the Office of the Clinical Director (OCD), Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), NIH provides clinical research support to (6) independent Laboratories/Clinical investigators, (4 Tenure Track/Unit Chiefs and 2 Senior Investigators/Branch Chiefs) and a recently formerly Core/Facility Head. In January 2022, both the Clinical Director and the Deputy Clinical Director stepped down and an Acting Clinical Director and Acting Deputy Clinical Director were appointed; both positions are now permanent appointments. Operational changes including personnel and workflow are currently underway including the transfer of participant recruitment to be managed internally following a non-renewal of a contract agreement with an outside vendor. The current Clinical research portfolio at the NIDA IRP includes a wide variety of collaborative investigation that focus on: Safety and efficacy of new treatments for addiction. Factors that impact drug taking and relapse. Application of MRI-based structural and functional imaging to elucidate acute and chronic drug effects and their consequences on cognitive processes. Molecular genetic bases of individual differences in vulnerability to develop dependence on an addictive substance. Development of advanced functional and structural magnetic resonance imaging/spectroscopy techniques. Structural MRI techniques to assess tissue integrity related to brain dysfunction. Transcranial magnetic Stimulation (TMS) in the elucidation and treatment of addictive disorders. Mobile health applications for real-time in-the-field addiction treatment interventions. The vision for the clinical portfolio of the NIDA IRP is to build a highly translational program that conducts cutting-edge addiction research aimed at improving our understanding of mechanisms related to addiction and developing new treatments for patients with substance use disorder, ranging from new behavioral approaches to new pharmacological and neuromodulation-based treatments. To implement this vision, among other actions, the following are critical goals under way: (1) create a unified and harmonized clinical portfolio; (2) build, foster, and support collaborative projects among the NIDA clinical PIs and preclinical PIs in the NIDA IRP; (3) build, foster, and support collaborative projects between the clinical PIs of the NIDA IRP and other clinical and preclinical PIs in other Institutes/Centers, Academia, and private sector; (4) make the clinical portfolio of the NIDA IRP a central component of the whole NIH IRP, by increasing its NIH-wide central role and visibility (including at the NIH main campus in Bethesda) via strong and longstanding scientific and clinical collaborations, as well as equally strong and longstanding collaborative regulatory, management and administrative efforts between the NIDA IRP and other NIH ICs/Centers/Offices; (5) serve as an exemplar of how to promote and sustain a culture of diversity, equity, inclusion, and accessibility (DEIA); (6) increase collaborations with the local Universities and boost community outreach engagement initiatives in the DC-Maryland-VA (DMV) area; and (7) create Academia-NIH joint clinical training program collaborations and contribute to addiction-related education/training for the future generations of clinicians and clinical scientists to advance addiction science and medicine. In summary, the vision for the NIDA IRP clinical portfolio is to build, foster, fortify and support a collaborative group of labs that span translational research via diverse approaches and methodologies, serving our collective goal to advance addiction science and medicine. This vision includes innovative clinical addiction studies, further corroborated via bidirectional translational projects to/from basic science, and further expanded via large population studies. The goal of the CD and their OCD team is to provide scientific clinical leadership and provide oversight, guidance, mentoring, and support aimed to strengthen an outstanding patient-driven group of scientists and clinicians with diverse and synergistic backgrounds, ranging from medicine and experimental psychology to neuroimaging, neuroscience, and health communication.